Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benserazide→

Benserazide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
322-35-0
Molecular formula
C10H15N3O5
Molecular weight
257.24 g/mol
Drug class
Peripheral aromatic L-amino-acid (DOPA) decarboxylase inhibitor
Mechanism of action
Inhibits peripheral DOPA decarboxylase and does not appreciably enter the central nervous system. When co-administered with levodopa, it reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the CNS and reducing the required levodopa dose. Benserazide alone has no antiparkinson activity.
Indications / reported uses
  • Used in combination with levodopa for Parkinsonism; benserazide is not an antiparkinson treatment by itself

Sources: NLM MeSH (Benserazide) · Health Canada product monograph listing for levodopa/benserazide

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benserazide Environmental Risk Assessment (ERA) (the Benserazide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.